國家藥監局發布第一版藥品網絡禁售清單 今起施行
國家藥監局發布關於藥品網絡銷售禁止清單(第一版)公告稱,自今日(1日)起施行。政策法規明確禁止銷售的藥品包括:疫苗、血液製品、麻醉藥品、精神藥品、醫療用毒性藥品、放射性藥品、藥品類易制毒化學品;醫療機構制劑、中藥配方顆粒。
國家藥監局綜合司發通知,要求各級藥品監管部門要梳理轄區內藥品網絡銷售企業和第三方平台情況,建立健全監管台賬,全面掌握轄區監管對象底數;要採取常規檢查、飛行檢查、交叉檢查等方式強化監管,並對配送企業等開展必要的延伸檢查;要加強跨地域藥品監管部門的協同配合,加強與公安、衛健、網信等部門的溝通協作,建立跨地域藥品網絡銷售案件協查機制和跨部門聯絡機制。(ta/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.